• UHIT Udruženje hematologa i transfuziologa

    UHIT Udruženje hematologa i transfuziologa

    Više
  • BIHEM smjernice

    BIHEM smjernice

    Više
  • UHIT novosti i događaji

    UHIT novosti i događaji

    Više

Bosansko-hercegovačka kooperativna grupa za hematološke bolesti

DASISION 4-Year Follow-up Continues to Show Superior Efficacy of Dasatinib vs Imatinib as Frontline Therapy for CML

 

DASISION 4-Year Follow-up Continues to Show Superior Efficacy of Dasatinib vs Imatinib as Frontline Therapy for CML



• 4-year safety and efficacy update of DASISION (CA180-056): randomized, open-label phase III trial[1]
Summary of Key Conclusions
• At 4-year follow-up, dasatinib continues to show superior efficacy vs imatinib as frontline treatment of chronic-phase chronic myeloid leukemia (CML)
o Deeper molecular responses
o More European LeukemiaNet (ELN)–defined optimal responses
o Fewer transformations to accelerated phase/blast phase (AP/BP)
• No new safety signals identified with dasatinib
• Exploratory landmark analyses suggest reducing BCR-ABL transcript to ≤ 10% on the International Scale (IS) at 3 months associated with better 4-year PFS and OS regardless of treatment
• Updated results continue to support dasatinib as an active, well-tolerated frontline therapy in CML
Background
• Early response to treatment important for long-term clinical benefit
• DASISION: superior efficacy of dasatinib 100 mg/day compared with imatinib 400 mg/day in newly diagnosed chronic-phase CML[2]
o Met primary endpoint: higher rates of confirmed complete cytogenetic response vs imatinib at 12 months
o Deeper and more rapid molecular response vs imatinib
• Current report is 4-year update of DASISION safety and efficacy with analysis of predictive potential of early molecular responses
Schematic of Study Design


Eligibility
• Philadelphia chromosome–positive, chronic-phase CML
o Biopsy confirmed
o Diagnosed within 3 months of study entry
• Previously untreated disease (hydroxyurea or anagrelide permitted)
• ECOG performance status 0-2
• Adequate organ function
Baseline Characteristics


• Patient disposition and discontinuations to date
o 4-year update: 11 patients in each arm discontinued between Years 3 and 4 


Description of Current Analysis
• Analysis update, minimum follow-up: 4 years
• Calculated cumulative molecular response rates by competing risk analysis in intent-to-treat population
• Progression and survival data collected at least annually after discontinuation for follow-up
o Progression defined as doubling of white blood cell counts, loss of response, Philadelphia chromosome–positive metaphases > 35%, transformation, or death from any cause
• Mutational analysis conducted at discontinuation or at time of clinically relevant events for extended analyses
• Retrospective and exploratory landmark analyses
• Reported P values have not been adjusted for multiple comparisons
Main Findings
• Dasatinib treatment associated with 1.6-fold higher likelihood of reaching major molecular response compared with imatinib (HR: 1.55; P < . 0001)
o Higher cumulative rate of major molecular response over 4 years (76%) vs imatinib (63%)
 At every time point assessed
 In every Hasford risk stratification group
o Patients receiving dasatinib also have higher 4-year cumulative rate of reaching MR4 and MR4.5 response levels, which are associated with improved long-term outcomes
• Fewer transformations to AP/BP CML in dasatinib arm


• 3-year exploratory analysis detected distinct patterns of BCR-ABL mutations in each arm
o Dasatinib: 18 mutations (4 unique) in 17 patients; 65% T315I
o Imatinib: 24 mutations (12 unique) in 18 patients
o Only 1 mutation (G250E) seen in both treatment groups
• No difference in estimated 4-year OS or PFS between treatment arms


• Dasatinib-treated patients achieved more ELN-defined optimal molecular responses and fewer failures compared with imatinib-treated patients at 3, 6, and 12 months
o Failure to achieve BCR-ABL ≤ 10%IS at 3 months associated with shorter 4-year PFS and OS


• Safety profile unchanged from previous analyses
o Pleural effusion, thrombocytopenia more common in dasatinib-treated patients; myalgia, edema more common in imatinib-treated patients
References
1. Cortes JE, Hochhaus A, Kim DW, et al. Four-year (yr) follow-up of patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Program and abstracts of the 55th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2013; New Orleans, Louisiana. Abstract 653.
2. Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2013;Epub ahead of print].


Udruženja hematologa i transfuziologa u FBiH

zvanična web stranica Udruženja

CIljevi Udruženja: praćenje razvoja dostignuća iz oblasti hematologije, transfuziologije i transplantacije i upoznavanje članova Udruženja sa novinama u cilju unapređivanja njihovih znanja i osposobljavanja, razvijanje etičke svijesti, morala odgovornosti i svijesti članova Udruženja u skladu sa kodeksom etike zdravstvenih radnika FBiH i međusobna razmjena mišljenja i iskustava u naučnom, stručnom radu iz područja hematologije i transfuziologije i srodnih naučnih disciplina.


Saznaj više
School Learning


    • Neutropenična dijeta

      Neutropenična dijeta je režim ishrane kojeg se pridržavate kad ste neutropenični. Važno je slijediti dijetu s niskom količinom sadržanih bakterija dok se imunološki sistem oporavlja.

      Više
    • Kako živjeti sa limfomom

      Brošura za pacijente u .pdf formatu. Šta je limfom? Koji je uzrok? Kako se postavlja dijagnoza?

      Više


    77

    članova


    16

    centara

    Our school goals

    Kako postati član?

    Poštovane kolege,

    pristupnicu je potrebno dostaviti poštom ili faksom te jedan primjerak odnijeti u računovodstvo ustanove u kojoj ste zaposleni da bi se vršila mjesečna uplata članarine.

    Više

    Kontakt telefon

    033 297 160

    Kontakt email

    info@uhit.ba